BioMarin Pharmaceutical Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

What happened

HC Wainwright & Co. kept its $60.00 per share price target on BioMarin Pharmaceutical, according to analyst ratings actions. This is an analyst target for the stock, not a company announcement or reported result.

Confirmed

Global impact / market context

A repeated price target tells investors that this analyst still expects the shares to reach $60.00 over time. It can influence buying and selling decisions, and may narrow the gap between the market price and that target.

Analyst inference

BioMarin is a drugmaker with high research costs, so analyst views on its stock often reflect expectations for its product pipeline and future revenue. A held target suggests no major change in that analyst's view.

Analyst inference

What to watch

1. Watch whether other analysts revise their price targets for BioMarin, since several targets together show a wider view of expected value. Confirmed
2. BioMarin could announce trial results or regulatory decisions that would give analysts a reason to raise or lower their targets. Proposed
3. Track BioMarin's spending on research and its cash available, because rising costs could push the stock away from the $60.00 target. Analyst inference

Evidence

• Original source link unavailable